Here's the frustrating truth about lung metastasis: the lung is immunologically weird. It has to tolerate constant exposure to airborne particles without overreacting, which makes it a naturally tolerogenic environment that suppresses anti-tumor immunity. T-cell-based therapies, the backbone of modern immunotherapy, often stall out here.
So what if the answer wasn't to import better immune cells, but to wake up the ones already living there? Alveolar macrophages (AMs) are the lung's permanent residents, the first responders of the alveolar airspace. They've always had the capacity to kill tumor cells. The question was: what's holding them back?
The answer is two phosphatases named PTPN1 and PTPN2. They act as a molecular brake on AM activation. A clinical-stage inhibitor called ABBV-CLS-484 (AC484) releases that brake, and what follows is a >50% reduction in lung metastatic foci across two independent mouse cancer models, without touching primary tumor growth.
Two spontaneous metastasis models, CMT167 lung carcinoma in C57BL/6 mice and 4T1 breast carcinoma in BALB/c mice, were treated daily with 20 mg/kg AC484 by oral gavage. Both models developed robust lung metastases. AC484 cut metastatic foci by >50% in both, confirmed by India ink staining and histological quantification.
The drug had no effect on primary tumor growth at these doses. That specificity matters: this isn't a cytotoxic effect, it's an immune-mediated one. The proof came from NSG mice, which lack functional T, B, NK, and myeloid cells. In that immunodeficient context, AC484 did nothing to metastasis in either model.
To rule out tumor-intrinsic effects, the team generated Ptpn1/2 double-knockout 4T1 cells via CRISPR/Cas9. These cells showed the expected increase in STAT1/STAT3 phosphorylation upon cytokine stimulation, confirming on-target editing. But mice bearing dKO tumors showed no reduction in metastasis without drug treatment, and AC484 suppressed metastasis in dKO-tumor mice just as effectively as in controls. The drug works through the host immune system, not the tumor.
Depleting CD8+ T cells or NK cells with antibodies had no effect on AC484's anti-metastatic efficacy. That result forced a harder look at the innate compartment. Single-cell RNA sequencing on 76,671 sorted lung cells from 4T1 tumor-bearing mice (three per group, harvested at Day 14) revealed a broad remodeling of the innate immune landscape.
Neutrophils shifted toward anti-tumor programs including degranulation and cytotoxicity signatures. NK cells enriched in AC484-treated animals showed elevated Ifng, Gzmb, and Prf1. But the most striking finding was a distinct alveolar macrophage cluster, AM3-AC484, that was specifically enriched after drug treatment and showed upregulated pathways for phagocytosis, reactive oxygen species production, and innate immune response.
This wasn't a subtle transcriptional nudge. Gene set enrichment analysis of AM3-AC484 showed coordinated upregulation of phagosome, lysosome, and oxidative phosphorylation pathways compared to the vehicle-enriched AM clusters. The drug was reprogramming the lung's resident macrophages toward a tumoricidal state.
scRNA-seq across 76,671 lung cells identified a specific alveolar macrophage subset, AM3-AC484, with an activated anti-tumor transcriptional program that emerges selectively after PTPN1/2 inhibition.
Single-cell data tells you what cells are doing. Spatial transcriptomics tells you where. Lungs harvested at Day 22 post-4T1 implantation showed microscopic metastatic nodules in vehicle-treated mice but not in AC484-treated ones. CellChat analysis of the spatial data identified AMs as the predominant signal receivers in the metastatic lung microenvironment, and the strength of those AM-centric interactions was amplified by AC484 treatment.
The spatial data also showed that AC484 significantly decreased the mean distance between AMs and disseminated tumor cells. Multiplex immunofluorescence confirmed the mechanism: AC484 selectively increased the density of CD68+/CD11b- AMs specifically within metastatic tumor regions, not in the surrounding parenchyma. These are the tissue-resident AMs, not recruited bone marrow-derived macrophages.
The functional proof came from in vivo depletion. Intranasal clodronate liposomes efficiently cleared AMs while sparing interstitial macrophages, T cells, and NK cells. In the 4T1 model, AM depletion completely abolished AC484's anti-metastatic efficacy. In CMT167-bearing mice, where T cells play a larger role, AM depletion roughly tripled lung metastases compared to non-depleted AC484-treated animals. Systemic CSF1R blockade, which depletes bone marrow-derived macrophages while sparing AMs, had no impact on AC484's efficacy, confirming that the lung-resident population is the active player.
With AMs established as the key effectors, the next question was the molecular pathway. Bronchoalveolar lavage fluid from AC484-treated 4T1-bearing mice showed a striking local increase in IFNγ, along with the downstream chemokines CXCL9 and CXCL10. This elevation was confined to the lung: serum IFNγ levels were unchanged. AMs from treated mice showed elevated intracellular IFNγ and CXCL9, suggesting they are both a source and a target of this local cytokine signal.
The sensitization effect was measurable ex vivo. AMs isolated from AC484-treated mice (484-AMs) showed significantly higher p-STAT1 (Y701) phosphorylation than vehicle-treated controls when stimulated with IFNγ or IFNα at 150 ng/mL. LPS stimulation, which normally produces only modest STAT1 activation in macrophages, triggered robust STAT1 phosphorylation and markedly higher CXCL9 production in 484-AMs, consistent with an IFNγ-primed state.
In co-culture assays, AC484 enhanced AM-mediated tumor cell killing in both 4T1 and CMT167 models at 72 hours. This killing required direct cell contact: separating AMs and tumor cells with a transwell insert substantially blunted the anti-tumor effect. The mechanism is contact-dependent, not soluble-factor-dependent.
Three lines of evidence locked in the IFNγ-JAK-STAT1 axis as the critical pathway. First, AMs from Ifng knockout mice retained baseline tumor-killing capacity but lost the AC484-enhanced killing. Second, the JAK1/2 inhibitor ruxolitinib blocked AC484-induced p-STAT1 upregulation and prevented the drug from enhancing AM cytotoxicity. Third, in vivo IFNγ neutralization phenocopied AM depletion, abolishing AC484's anti-metastatic effect in the 4T1 model. In CMT167-bearing IFNγ knockout mice, AC484 achieved only a ~20% reduction in metastasis compared to >85% in wild-type controls.
PTPN1/2 inhibition works through a dual mechanism: it increases local IFNγ production in the lung and sensitizes AMs to that signal, driving amplified STAT1 phosphorylation and contact-dependent tumor killing. Block IFNγ or JAK signaling, and the drug stops working.
The model that emerges is clean. PTPN1 and PTPN2 dephosphorylate JAK kinases, dampening the amplitude and duration of IFNγ signaling in AMs. AC484 blocks that dephosphorylation, releasing the brake. The result is a macrophage population that produces more IFNγ, responds more strongly to IFNγ from neighboring cells, and physically moves into metastatic lesions to kill tumor cells on contact.
What makes this therapeutically interesting is what it bypasses. The 4T1 model is notoriously resistant to anti-PD1 therapy, and combining AC484 with anti-PD1 provided no additional benefit in that model. The drug works through innate immunity, not adaptive immunity. For patients whose tumors have already evaded T-cell surveillance, reactivating tissue-resident macrophages represents a genuinely orthogonal strategy.
AC484 is currently in Phase 1 clinical trials. As an orally bioavailable small molecule, it's a practical candidate for adjuvant settings, potentially controlling micrometastatic disease after surgery. The authors also flag that PTPN1/2 regulate IL-6, IL-2, and Type I IFN pathways, which opens the door to applications in infectious and inflammatory lung disease beyond oncology.
One honest caveat: this work is entirely in mouse models, and the two models used have quite different immune landscapes. The relative contribution of AMs versus other innate cells likely varies by tumor type and metastatic site. Whether this mechanism translates to human AMs, and whether the IFNγ-STAT1 axis behaves the same way in the human lung microenvironment, remains to be tested in the clinic.
